Biovica's blood test provides new answers for cancer care
Cancer diagnostics is facing a shift that could have a major impact on both healthcare practices and treatment outcomes – and Biovica...
Green light for PHI to step up its commercial strategy
Phase Holographic Imaging (PHI) has now formally decided...
Enzymatica's CEO comments on his resignation
Claus Egstrand leaves the role as CEO of Enzymatica...
Rights issue strengthens AlzeCure's position
AlzeCure Pharma is conducting a rights issue of SEK 48,5 million,...
AI-designed proteins are created in seconds
Australian researchers have used artificial intelligence...
The price of Leqembi needs to be lowered in Japan
A new analysis from Japan's Center for Outcomes...
BioStock Global Forum 2025 – watch the videos
Investing in biotech – an article series
AlzeCure Pharma: “We have good momentum”
AlzeCure Pharma, which develops small molecule drugs for the treatment of...
Modus Therapeutics CEO comments on latest milestone
Modus Therapeutics has completed recruitment for the first...
The new era of weight loss: Does GLP-1 live up to expectations?
GLP-1 drugs such as Wegovy and Mounjaro have been globally acclaimed...
Notes
Cantargia publishes data for nadunolimab in lung cancer
Genmab reports sales of DARZALEX
AlzeCure receives additional subscription commitments of SEK 7 million
AstraZeneca updates on phase III study
Orexo maintains full-year forecast despite currency headwinds
BioGaia launches subsidiary for microbiome research
Isofol receives positive FDA feedback for arfolitixorin
NEWSLETTER
Upcoming events
Investing in Life Science
Discover unparalleled opportunities, set in the vibrant heart of Stockholm. This premier event unites forward-thinking investors and business leaders to...
Life Science Summit
The Nordic region's leading forum for early-stage and growth-phase life science companies. The Summit bridges innovation and capital by providing...
Recommended
Trump threatens 200 percent tariffs on pharmaceuticals
AbbVie acquires Capstan Therapeutics for up to $2,1 billion
GLP-1 drugs drive pharmaceutical boom to 2030
FDA introduces fast track for drugs of national importance
Monetization of future royalties increasingly popular
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account
Today's news roundup
